On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE ... at risk of rapid disease progression. In ...

London: The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease ... The FDA's latest approval ...

Novartis NVS ... from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney disease. The approval follows ...

The FDA approved Ardelyx Inc's (NASDAQ: ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease ...

The company had focused its resources on Filspari’s launch in IgAN after the US FDA snubbed the therapy in another rare ...

The US FDA has approved a new orphan drug to treat patients with Cushing’s disease who cannot be helped through surgery. Novartis’ Signifor (pasireotide diaspartate) injection has been ...

(Reuters) -The U.S. Food and Drug Administration has approved the use of Novartis’ drug to reduce excess protein in the urine of patients with a type of kidney disease, the health regulator’s website ...

the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A ...